Compare Sana Biotechnology Inc (SANA) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vistra Corp — how do they compare? Sana Biotechnology Inc trades at $3.19 (market cap $947.48M), while Vistra Corp trades at $150.85 (market cap $50.71B). The key difference: Vistra Corp is far larger — about 53.5× Sana Biotechnology Inc's market cap, and Vistra Corp pays a 0.61% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | VST | |
|---|---|---|
Market Cap | $947.48M | $50.71B |
Sector | Health | Technology |
52-Week High | $5.92 | $217.92 |
52-Week Low | $2.68 | $134.71 |
Enterprise Value | $860.73M | $72.65B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $244.17 million for 2025, with ROE at -152.87%. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data for type 1 diabetes treatment.
Analyst consensus is strongly bullish with 81.82% buy ratings, but high cash burn and negative earnings pose significant risks. Upside potential hinges on clinical success and future profitability, while downside risks include sustained losses and competitive pressures in biotechnology.
Vistra Corp. (VST) trades at $151.72, up 1.62% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $228.40. Recent earnings show volatility with a Q1 2026 beat but Q2 2026 miss, while fundamentals highlight strong profitability with an 11.55% net income margin and 75.73% ROE. The company benefits from long-term power agreements with tech giants like Amazon and Meta, driving revenue growth to $19.2 billion in 2026.
VST presents a compelling opportunity with significant upside potential based on analyst targets, though risks include regulatory uncertainty and earnings inconsistency. The stock's valuation multiples like P/E of 25.48 are reasonable given growth prospects, but investors must weigh execution risks against AI-driven power demand tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
